Company: WHWK
Filing Date: 2025-03-06
Form Type: SCHEDULE 13D/A
Source: 0000950170-25-034969
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-06
Form: SCHEDULE 13D/A
Chunk 0
---
 shares (See Instructions) |
| 13                                                                 |                                                                                4.9 % |
| 14                                                                 |                                                                                   IN |

Comment for Type of Reporting Person: (1) Consists of 461,700 shares of Common Stock issuable upon exercise of options exercisable within 60 days of March 4, 2025, subject to Dr. Desai's continued service through each vesting date. (2) Consists of 639,698 shares of Common Stock directly owned by the Anishka Irrevocable 2016 Trust dated October 19, 2016 (the "Anishka Irrevocable Trust") and 1,171,543 shares of Common Stock directly owned by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Anishka Family Trust"). Dr. Desai and his spouse share voting and dispositive power over the shares held by the Anishka Irrevocable Trust and the Anishka Family Trust and each of Dr. Desai and his spouse is a trustee of the Anishka Irrevocable Trust and the Anishka Family Trust. (3) Based on the quotient obtained by dividing (a) the aggregate number of shares of Common Stock beneficially owned by Dr. Desai by (b) the sum of (i) 46,294,912 shares of Common Stock outstanding as of March 4, 2025, based on information provided to Dr. Desai by the Issuer, and (ii) 461,700 shares of Common Stock issuable upon exercise of options exercisable within 60 days of March 4, 2025 held by Dr. Desai. The aggregate number of shares of Common Stock beneficially owned by Dr. Desai as set forth in clauses "(a)" and "(b)" of this footnote are treated as outstanding shares of Common Stock only for the purpose of computing the percentage ownership of Dr. Desai.

| SCHEDULE 13D |

| Item 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Security and Issuer                                                                                                                                                                                                                                                                                                                                                                                            |
| (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Common stock, par value $0.0001 per share                                                                                                                                                                                                                                                                                                                                                                      |
| (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Aadi Bioscience, Inc.                                                                                                                                                                                                                                                                                                                                                                                          |
| (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17383 Sunset Boulevard, Suite A250, Pacific Palisades,